| May 15, 2025 |
May 16, 2025 |
EXELIXIS, INC.
|
EVP Prod Dev & Med Aff & CMO |
Sell |
17.5
|
-81,079
|
-7.76%
|
✗
|
$3.7M |
| Nov 15, 2024 |
Nov 19, 2024 |
EXELIXIS, INC.
|
EVP Prod Dev & Med Aff & CMO |
Sell |
20.0
|
-27,224
|
-8.45%
|
✗
|
$954.2K |
| Mar 16, 2023 |
Mar 20, 2023 |
CytomX Therapeutics, Inc.
|
EVP, Chief Development Officer |
Sell |
47.5
|
-4,257
|
-6.79%
|
✗
|
$8.4K |
| Jul 19, 2022 |
Jul 21, 2022 |
CytomX Therapeutics, Inc.
|
EVP, Chief Development Officer |
Sell |
91.3
|
+12,537
|
25.00%
|
✗
|
$10.6K |
| Dec 17, 2018 |
Dec 19, 2018 |
BeOne Medicines Ltd.
|
CMO, Immuno-oncology |
Sell |
23.8
|
-20,000
|
-7.66%
|
✓
|
$2.7M |
| Nov 8, 2018 |
Nov 13, 2018 |
BeOne Medicines Ltd.
|
CMO, Immuno-oncology |
Sell |
20.0
|
-40,000
|
-12.78%
|
✓
|
$4.8M |
| Aug 23, 2018 |
Aug 24, 2018 |
BeOne Medicines Ltd.
|
CMO, Immuno-oncology |
Sell |
38.8
|
-5,769
|
-2.88%
|
✓
|
$975.7K |
| Nov 13, 2017 |
Nov 15, 2017 |
BeOne Medicines Ltd.
|
CMO, Immuno-oncology |
Sell |
42.5
|
-3,601
|
-1.58%
|
✓
|
$298.7K |
| Aug 22, 2017 |
Aug 24, 2017 |
BeOne Medicines Ltd.
|
CMO, Immuno-oncology |
Sell |
42.5
|
-28,185
|
-9.40%
|
✗
|
$151.8K |